Skip to main content
. Author manuscript; available in PMC: 2014 Jan 20.
Published in final edited form as: Gastroenterology. 2008 May 7;135(2):370–379. doi: 10.1053/j.gastro.2008.04.036

Table 4.

Biomarker Predictors of Absence of Dysplasia and Adenocarcinoma at 3-Month Follow-Up Evaluation

Biomarker OR (95% CI)
P16 loss 0.25 (0.09–0.75)
P53 loss 0.45 (0.16–1.32)
C-MYC gain 1.07 (0.44–2.56)
HER2-NEU gain 0.60 (0.03–44.00)
20 q gain 0.50 (0.01–37.49)
Multiple gains 0.15 (0.01–3.72)

OR for each biomarker adjusted for the following clinical variables: age, sex, Barrett’s segment length, PDT, and EMR.